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Abstract 
Objective 
There is little randomized controlled trial (RCT) evidence to guide treatment for anxiety after 
stroke. We systematically reviewed RCTs of anxiety interventions in acquired brain injury 
(ABI) conditions including stroke and traumatic brain injury (TBI) in order to summarize 
efficacy and key aspects of trial design to help guide future RCTs. 
Methods 
We searched the Cochrane trial register, Medline, Embase, PsychInfo and CINAHL 
systematically up to August 2017. Two independent reviewers systematically selected studies 
and extracted data. We summarized the effect size, key study characteristics and sources of 
potential bias in trial design. 
Results 
14 studies (12 stroke; one stroke & TBI; one TBI) with 928 participants were included. Meta-
analysis of five psychotherapy comparisons favoured intervention over control (standardized 
mean difference (SMD): -0.41 [-0.79, -0.03], I2= 28%); Overall effect size of 
pharmacotherapy comparisons favoured intervention over control (SMD: -2.12[-3.05, -1.18], 
I2 = 89%). One comparison of mixed pharmacotherapy and psychotherapy favoured 
intervention over usual care (SMD -4.79[-5.87, -3.71]). One comparison favoured forest 
therapy versus urban control (SMD: -2.00[-2.59, -1.41]). All positive studies carried high or 
unclear risk of bias. Sample sizes were small in all included studies.  
Conclusions 
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There is low quality evidence to suggest that psychotherapy and pharmacotherapy may be 
effective interventions in the treatment of anxiety after stroke based on underpowered studies 
that carried high risk of bias. Large-scale well-designed definitive trials are needed to 
establish whether pharmacological or psychotherapy works. Our review highlighted key 
considerations for investigators wishing to design high quality trials to evaluate treatments for 
anxiety after stroke. 
Keywords: anxiety, stroke, neuropsychiatric, intervention, rehabilitation, clinical trial 
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Introduction 
Anxiety is a common neuropsychiatric complication of stroke with an estimated frequency 
between 20-25% (1). There are two main subtypes of anxiety—phobic and generalized in 
non-stroke populations, requiring different treatment approaches. Phobic disorder is 
characterized by fear disproportionate to the threat posed by a well-defined situation, and 
marked avoidance of the situation(2). Generalized anxiety disorder (GAD) presents with 
diffuse anxiety about events of daily life that is persistent and unremitting that the individual 
finds difficult to control(2). In the general population, phobic disorder is treated with 
exposure techniques(3) whereas GAD responds to selective serotonin reuptake inhibitors 
(SSRI), short-term benzodiazepines and/ or other cognitive behavioural therapy (CBT) 
techniques e.g. cognitive restructuring, problem solving(4, 5). Randomized controlled trials 
(RCTs) of anxiety intervention in stroke have not yielded any definitive evidence in a recent 
Cochrane review—only three trials (2 pharmacological, 1 relaxation CD) with 196 
participants were included(6). These had high risk of bias and were of small sample size. 
Aware of the lack of RCT evidence in anxiety after stroke we aimed to review systematically 
the wider evidence base encompassing both stroke and traumatic brain injury (TBI). To date, 
there is no evidence to suggest that pathophysiological mechanism underlying anxiety 
disorders differs from one acquired brain injury (ABI) condition to another.  The last 
systematic review of anxiety interventions in TBI in 2007 included three studies, providing 
some evidence for CBT in acute stress disorder, and in improving generalized anxiety 
symptomology but these studies had small sample sizes and were done in mild TBI only(7). 
The current review would enable us to extrapolate from one ABI to the other as these 
conditions have abrupt onset, result in varying degrees of brain damage, and transient or 
long-term neurological and neuropsychiatric impairments. Furthermore, summarizing the key 
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considerations in trial design (anxiety subtype targeted, setting and timing of intervention and 
outcome measure), and the sources of potential bias would help guide trialists to design high 
quality trials to evaluate anxiety treatments in the future.  
Aims 
To evaluate the efficacy of anxiety treatments and to summarize key aspects of trial design, 
we systematically reviewed RCTs of interventions—psychotherapy, pharmacotherapy or 
other types, for anxiety disorders in ABI conditions including stroke—ischaemic, 
haemorrhagic or subarachnoid haemorrhage (SAH), and TBI.  
Methods 
We followed a pre-defined protocol in conducting this systematic review and reported our 
review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) checklist(8).  
Searches and information sources 
We searched electronically for RCTs on Medline (1946-18/8/17), Embase (1980-17/8/17), 
PsychInfo (1940-17/8/17), the Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) (inception-16/10/17), the Cochrane Stroke Register (16/10/17), and the Cochrane 
Central Register of Controlled Trials (CENTRAL) (inception-16/10/17) using search 
strategies supplied by the trials search co-ordinator of the Cochrane Stroke Group 
(Supplement B). We reviewed the reference list of key systematic reviews to date to identify 
additional titles(6, 7). We contacted authors of eligible titles that were trial protocols, 
conference abstracts or trial register entries for published or unpublished primary data.  
Inclusion criteria 
We included RCTs that evaluated interventions designed to target anxiety symptoms/ anxiety 
disorder as a primary outcome, with any comparator group (placebo, usual care, waitlist 
control, active comparator). We included RCTs that recruited participants aged 18 or over 
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with ABI conditions: ischemic or haemorrhagic stroke; SAH, confirmed by brain imaging 
with or without a lumbar puncture; moderate-to-severe TBI as defined according to the 
Scottish Intercollegiate Guidelines Network(9). We excluded mild TBI, a clinical group that 
is difficult to diagnose reliably(10). Where studies were carried out in a mixed sample, we 
included only those that recruited over 70% of stroke/SAH/ moderate-to-severe TBI. We 
excluded trials that recruited exclusively military veterans. No language restrictions were 
applied. 
Data collection  
Two reviewers (HYYC and RN) screened titles and abstracts independently and excluded 
ineligible titles. They assessed full text for eligibility and resolved discrepancies through 
discussion. A third reviewer (AJC) was consulted if a consensus could not be reached. They 
extracted data independently using an electronic data extraction form. HYYC collated final 
data. One reviewer (HYYC) assessed studies that were only available in Chinese. 
Data extracted 
We recorded key characteristics of the study population: ABI diagnosis, age, sex, exclusion 
of specific deficit, baseline anxiety level, and intervention type (e.g. psychotherapy, 
pharmacotherapy, other). 
Quality assessment  
We reported the level of bias across six domains of study design for the included studies: (A) 
random sequence generation, (B) allocation concealment, (C) blinding of participants and 
personnel, (D) blinding of outcome assessment (E) incomplete outcome data, and (F) 
selective reporting. We categorised the level of bias into ‘low’, ‘high’ or ‘unc lear’ and 
recorded justification for our judgement for each domain in accordance with the Cochrane 
Risk of Bias Tool (http://methods.cochrane.org/bias/assessing-risk-bias- included-studies).  
Efficacy of intervention  
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We estimated effect size for each comparison by calculating the standardized mean difference 
(SMD) with 95% confidence intervals (CI) using the mean and standard deviation (SD) of the 
post-intervention anxiety severity. Meta-analysis was carried out for studies of the same 
intervention type using inverse variance and random-effects models. All analysis was 
performed using the Cochrane Review Manager (RevMan) Version 5.3(11). Where data were 
not reported in study publication we contacted the corresponding authors for further 
information.  
Key study characteristics and potential bias in trial design 
We summarized the key study characteristics: anxiety type targeted, the setting and timing of 
intervention, outcome measures, the type of comparator, and ways that could have introduced 
or minimized potential bias in study design 
Results 
The electronic searches yielded 8218 titles after removal of duplicates (Figure 1). Of the 59 
full text articles reviewed, we included 14 eligible studies with 928 participants. Sample size 
ranged from 17 to 206. Four studies were in Chinese(12-15). No clear evidence of publication 
bias on funnel plot (Supplement C). 
Characteristics of study population 
Table one summarizes the characteristics of the 14 included studies. 12 studies recruited 
stroke patients only (ischaemic and primary haemorrhage)(12-23), one study recruited stroke 
and moderate-to-severe TBI(24), and one study recruited moderate-to-severe TBI only(25). 
No study recruited patients with SAH. The mean age ranged from 48 to 72 years in studies of 
stroke patients only, and from 35 to 58 years in the two studies that included TBI patients. 
More men than women were recruited in all included studies. 12 studies excluded patients 
with communication difficulties due to aphasia or cognitive impairment(12-14, 16-22, 24, 25); 
one yoga exercise intervention excluded participants who were unable to ambulate 
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independently(17). Seven studies required participants to have a baseline diagnosis of anxiety 
disorder or ‘emotional distress’ either made on standardized diagnostic criteria e.g. 
Diagnostic Statistical Manual (DSM-IV TR), or by meeting a defined cut-off on a rating 
scale(12, 13, 19, 22-25). Six studies did not specify a baseline anxiety level for inclusion (14-
18, 20). One study of a preventative intervention excluded the diagnosis of GAD on DSM-IV 
TR at baseline(21).  Studies used different anxiety rating scales at baseline and outcome 
assessment (Table 1): Hamilton Anxiety Rating Scale (HAMA) in five studies (12, 13, 15, 21, 
23), Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A) in three studies (19, 
20, 25); State-Trait Anxiety Inventory (STAI) in three studies (16-18); Depression Anxiety 
Stress Scales (DASS) in one study(24); Zung Self-rating Anxiety Scale (SAS) in one 
study(14); Beck Anxiety Inventory (BAI) in one study(22).  
Quality assessment 
None of the 14 studies scored ‘low’ risk of bias across all six domains (A-F) of study design 
(Figure 2). Three studies scored ‘low’ risk across five domains (20, 21, 25). Two studies 
scored ‘low’ risk across four domains(22, 24). One studies scored ‘low’ risk across three 
domains(17). Eight studies scored ‘low’ risk on fewer than three of the six domains(12-16, 18, 
19, 23), including six studies that scored ‘high’ risk or ‘unclear’ risk across all six 
domains(12-16, 23). 
Efficacy of intervention  
The 14 included studies provided 19 comparisons: eight psychotherapy(14, 20-22, 24, 25), 
five pharmacotherapy(12, 13, 15, 21), one combined pharmacotherapy and 
psychotherapy(12), two exercise(16, 17), and three other interventions(18, 19, 23). We 
carried out meta-analyses for psychotherapy and pharmacotherapy studies. 
Psychotherapy  
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Six studies provided eight comparisons of psychotherapy interventions, the content of each is 
summarized in Table 1.  Data were not available for three comparisons after contacting study 
authors. Meta-analysis of the five comparisons showed an overall positive effect favouring 
psychotherapy intervention over control (SMD: -0.41 [95%CI -0.79, -0.03]). I2 statistic of 28% 
suggests a low-to-moderate level of heterogeneity across studies (Figure 2). The only study 
that demonstrated an effect favouring ‘psychotherapy’ over usual care(14) received ‘unclear’ 
risk of bias across all six domains of study design. The remaining four neutral comparisons 
(one ‘brief positive psychotherapy’ versus usual care(24), one ‘motivational interviewing & 
CBT’ versus usual care(25); one ‘non-directional counselling & CBT’ versus usual care(25), 
one ‘computerised CBT’ versus computerized cognitive remediation therapy(22)) received 
‘low’ risk of bias across at least three domains of study design; all had small sample sizes. 
One comparison not included in our analysis reported that group receiving placebo was four 
times more likely to develop GAD compared to ‘problem-solving’ therapy (adjusted hazard 
ratio: 4.00 [95%CI 1.84, 8.70])(21). The other two comparisons not included in our analysis 
reported a non-statistically significant reduction in adjusted mean HADS-anxiety score with 
psychotherapy: ‘coping skills’ vs usual care (-0.5, [95%CI -2.0, 1]); ‘self-management’ vs 
usual care (-0.6, [95%CI -2.0, 0.8]) (20).  
Pharmacotherapy  
Four studies provided five comparisons of pharmacotherapy versus control, data were not 
available in one comparison after contacting study author(21). Meta-analysis of these four 
comparisons showed an overall effect favouring pharmacotherapy intervention over control 
(SMD: -2.12 [95%CI -3.05, -1.18]). I2 statistic of 89% suggests a high level of heterogeneity 
across studies. Two of these comparisons were between paroxetine, an SSRI and usual care 
(12, 13). One comparison was between imipramine, a tricyclic antidepressant and usual 
care(13). One study compared buspirone, an azapirone anxiolytic with usual care (15). All 
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four comparisons are from three studies which scored ‘high’ risk or ‘unclear’ risk of bias 
across all domains of study design. The study without available data for analysis reported an 
increased reported that group receiving placebo was four times more likely to develop GAD 
compared to escitalopram (adjusted hazard ratio: 4.95 [95%CI 1.54-15.93])(21).  
Combined pharmacotherapy and psychotherapy  
One comparison of combined paroxetine and psychotherapy with usual care demonstrated a 
large effect favouring combined therapy (SMD -4.79 [95%CI -5.87, -3.71])(12). This study 
scored ‘unclear’ and ‘high’ risk of bias across all six domains of study design. 
Exercise intervention 
Two studies evaluated exercise interventions, One study compared yoga and exercise with 
exercise only and showed a neutral effect(17). One study on resistance exercise reported 
lower state anxiety favouring resistance exercise over usual care but data were unavailable 
for calculating SMD after contacting the study author(16). Both studies had small sample 
sizes. The yoga study scored ‘low’ risk of bias across three domains of study design and the 
study on resistance exercise scored ‘high’ and ‘unclear’ risk of bias across all six domains. 
Other therapies 
One study compared acupuncture with alprazolam (23), one study compared relaxation CD 
with waitlist control(19). Both of these studies were neutral. The study of acupuncture scored 
‘unclear’ risk of bias across all six domains, and the study of relaxation CD scored ‘high’ risk 
of bias across more than three domains of study design. One study compared forest therapy 
with urban control and demonstrated an effect favouring forest therapy (SMD: -2.00 [-2.59, -
1.41]). This study scored ‘high’ risk of bias on four domains of study design. All three studies 
had small sample sizes.  
Key study characteristics  
Anxiety subtype targeted  
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One study specified GAD as the target of its interventions (escitalopram; problem solving 
therapy)(21). No study targeted phobic disorder. Two studies of pharmacotherapy (SSRI, 
TCA), and combined pharmacotherapy (SSRI) and psychotherapy specified a diagnosis of 
‘mixed anxiety and depression’ as an inclusion criterion and had positive results (12, 13). 
Two studies of psychotherapy (brief positive psychotherapy; computerized CBT) targeted 
‘emotional distress’—anxiety and/or depression and were neutral (22, 24). One study of 
acupuncture and alprazolam targeted ‘post-stroke neurosis’ which is now a defunct 
diagnosis(23). The remaining eight studies targeted ‘anxiety’ without subtyping(14-20, 25), 
three of them were positive(14, 15, 18). 
Setting of intervention 
Seven studies were carried out in the community(16-19, 21, 22, 25), three studies in an 
inpatient setting(12, 13, 15), two in outpatient clinic(23, 24), and one commenced in an 
inpatient setting then continued in the community(20). One study did not report setting of the 
intervention (14). Only one community-based study was positive (18). All three inpatient 
studies and the study with unknown setting were positive.  
Timing of intervention since injury 
Seven studies specified time since injury as an inclusion criterion: ‘acute stroke’ (12), within 3 
months(21);  between 3-36 months(24); anytime within 5 years(22); at least 6 months(17);  at 
least one year(16, 18).  The actual time of intervention since injury in the studied sample 
ranged from 15 days to 13 years. Of the five positive studies, three did not report timing of 
intervention since injury in studied samples, one study reported intervention at 21 days from 
injury(12), and one reported intervention at 140-150 months(18).  
Timing of outcome measures 
Eight studies measured anxiety outcome at the end of the intervention(12, 13, 15-18, 23, 25). 
Other studies measured primary outcome at various time points post- intervention: 2 weeks; 8 
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weeks; 12 weeks; 12 months. Four of the five positive studies measured primary outcome at 
the end of intervention(12, 13, 15, 18) and one measured at two weeks post-intervention(14). 
Comparator  
‘Usual care’ was the most commonly used control condition. Four studies used an active 
comparator(17, 18, 22, 23) and one study used a placebo control(21). Four of the five positive 
studies used ‘usual care’ as control conditions(12-15) and one used an active control(18).  
A summary of sources of potential bias in study design 
A) Random sequence generation 
Studies scoring ‘unclear’ risk of bias in this domain only reported that patients were 
randomly allocated but did not give detail on how, and by whom the randomisation sequence 
was generated. Studies scoring ‘low’ risk reported the type of randomisation carried out e.g. 
computerized randomisation, stratified randomisation with blocking, random number 
generator, and by whom the randomisation was performed e.g. person external to the study/ 
independent of the study 
B) Allocation concealment 
Studies scoring ‘high’ risk of bias reported that it was the study personnel who performed 
randomisation and provided the treatment allocation. Studies scoring ‘low’ risk reported 
methods that would prevent the study team from knowing the allocation in advance e.g. 
allocation informed via mailed letters by external person who carried out randomization, 
study personnel were blinded to randomization block length with randomisation performed 
externally, use of opaque/ sealed envelopes pre-filled by person independent of the study.  
C) Blinding of participants and personnel 
Most studies scored ‘high’ risk in this domain as blinding of participants was rarely attempted. 
The most common comparator group was ‘usual care’. We considered participant blinding 
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sufficient in the study that used computerised CRT as a comparator of computerised CBT, 
and the study that used placebo as a comparator of escitalopram.  
D) Blinding of outcome assessment 
Studies scoring ‘high’ risk reported outcome assessment being performed by the same study 
personnel that delivered the interventions. Studies that scored ‘low’ risk reported methods to 
blind outcome assessment e.g. a second research assistant performed outcome assessment 
using a standard script to prevent unblinding, use of self- rated questionnaires and data entry 
by blinded assessor. 
E) Incomplete outcome data 
All studies scoring ‘high’ risk lost follow-up data (attrition ranged from 2 – 22%) and did not 
perform intention-to-treat analysis. Reasons for attrition were: personal reasons, additional 
health concerns/ injury unrelated to intervention, improved mood, other commitments, lack of 
time, found it distressing to talk about difficulties, wish to discontinue involvement.  
F) Selective reporting 
We examined the published trial protocol, if available, for each included study to detect 
whether selective reporting was present. One study scoring ‘high’ risk reported results on 
anxiety from the same study in an earlier publication that evaluated intervention for 
depression prevention. 
Discussion 
Our findings suggest efficacy of psychotherapy and pharmacotherapy interventions in the 
treatment of anxiety after ABI. The positive effect sizes were driven entirely by studies of 
low quality. These findings alone are not definitive evidence to guide treatment of anxiety 
after stroke. Compared to previous systematic reviews in stroke and TBI (6, 7) we opted to 
include studies from a broader ABI population encompassing stroke (ischaemic, primary 
haemorrhage, SAH) and moderate-to-severe TBI, and included a wider continuum of baseline 
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anxiety levels (i.e. not limited to patients with a baseline anxiety diagnosis). This approach 
led to more studies to be included in our review, and enabled us to meta-analyse results for 
the same type of anxiety interventions for the first time. Furthermore, we found studies that 
were better reported and of better quality which were excluded in the previous reviews. This 
enabled us to summarize key aspects of trial design and measures to minimize bias in order to 
help guide trialists in designing high quality RCTs in the future. 
Intervention design 
Anxiety subtype targeted  
Studies have targeted ‘mixed anxiety and depression’, ‘emotional distress (anxiety and/or 
depressive symptoms)’, or ‘anxiety’. Only one study specified the prevention of GAD as the 
target of intervention. No studies targeted phobic disorder.  
Phobic disorders e.g. agoraphobia may be more common than GAD after stroke(1). 
Intervention design should reflect the treatment approaches known to be effective at treating 
these anxiety subtypes in non-stroke populations. Anxiety with a phobic element invariably 
requires some form of behavioural therapy with exposure work, while generalized anxiety is 
treated with other CBT techniques e.g. cognitive restructuring, problem solving, and/or 
medications e.g. SSRI. 
Although the content of psychotherapy interventions varied across our included studies, the 
majority of interventions consisted of some form of, or a combination of psychoeducation, 
skills learning e.g. problem solving, positive psychology, therapeutic exercises, and CBT.  
Interventions for anxiety after stroke should encompass components that aim to address the 
symptomology of both phobic and generalized anxiety subtypes. 
A variety of anxiety rating scales were used to assess primary outcome in our included 
studies. These are validated for generalized anxiety and none for the phobic subtype. The 
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choice of outcome measures should reflect both types of anxiety symptomology given that 
phobic disorder is also common after stroke.  
Setting and timing of intervention, and timing of outcome measures 
Most of the positive studies were carried out in an inpatient setting and measured primary 
outcome immediately post-intervention. This approach does not address the consistent 
finding from other studies that anxiety continues to be frequent at six-months or more post-
stroke(1) and cannot generalize to patients who have returned to living in the community. An 
anxiety intervention should aim to relieve anxiety and its debilitating impact on stroke 
patients in the long-term. Determining the best time of outcome measure should be based on 
this goal, and be balanced against the feasibility of study procedures to ensure completion of 
long-term follow-up. We suggest that outcome measures should be taken at the end of the 
intervention and then after a period with no treatment to see whether any benefits are 
sustained. 
Measures to minimize bias  
Most of the positive studies in our review were poorly reported across all aspects of study 
design on the Cochrane bias assessment tool. All trialists should adhere to standardized 
reporting guidelines e.g. CONSORT checklist on RCTs, and the TiDier (Template for 
Intervention Description and Replication) checklist when evaluating complex interventions, 
both of which can be found on the EQUATOR (Enhancing the QUAlity and Transparency of 
health Research network) website: http://www.equator-network.org/reporting-
guidelines/consort/. 
Participant blinding and control conditions 
Most of our included studies did not attempt participant blinding. ‘Usual care’ was the 
commonest comparator in our review and in four out of the five positive studies. The 
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description of what constituted ‘usual care’ was minimal across our included studies. ‘Usual 
care’ and waitlist controls have been shown to exaggerate effect size in meta-analyses of 
trials evaluating psychotherapy(26). A recently published transparent decision framework 
help guide trialists select the appropriate type of control based on several factors: participants’ 
interests (expected benefit, or harm or worsening of symptoms induced by the control 
condition), the researchers’ interests (available resources, maximizing validity of findings), 
and trial purpose (e.g. phase 2, phase 4) (27). Placebo is the gold-standard comparator for 
pharmacotherapy intervention. In a trial of psychotherapy or other non-pharmacological 
intervention, an active comparator or another established treatment that is known to be 
effective and widely available in the ‘real world’ would be more appropriate as a control in 
phase 3 or phase 4 (pragmatic/ real world) trials(27).  
Other measures to minimize bias 
Some included studies provided examples of good practice in minimizing bias in other 
domains: external personnel to randomize patient; allocation concealment to ensure study 
personnel cannot foresee allocation while recruiting; use of outcome assessors blinded to 
allocation; use of standard script at telephone follow up to prevent unblinding; use of self-
completed outcome measures; data input by blinded external assessor; reporting missing data 
and methods for handling missing data; intention-to-treat analysis; publishing protocol on 
trial registries. Studies should also provide detailed description of the experimental 
intervention and control condition to ensure standardized procedures are given to all 
participants of each arm e.g. use of manuals. Adherence to the allocated treatment and any 
deviation from standardized procedures should be recorded and reported. 
Study limitations 
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Data for calculating SMDs were missing in four comparisons despite contacting 
corresponding authors. We included one mixed ABI (strokes in >85% of intervention and 
control groups), and one TBI-only samples. Almost all studies excluded patients who had 
communication impairments e.g. dysphasia, cognitive impairment, and varied in settings, 
timing since injury, timing of outcome measures, limiting the generalizability of our findings. 
Considerations for future studies 
Compared to pharmacological interventions, psychological or behavioural interventions pose 
unique challenges in trial methodology, both in its execution and in bias minimization. While 
the current review cannot provide definitive evidence on efficacy of anxiety treatments in 
stroke due to poor study quality and small sample sizes of the included studies, we provided a 
summary of key considerations in trial design (anxiety type targeted, setting, timing of 
intervention and outcome measure, methods to minimize bias) to guide trialists and clinicians 
on what would constitute a high quality RCT. High quality definitive RCTs of sufficient 
sample size are now warranted to evaluate psychotherapy and pharmacotherapy interventions 
in the treatment of anxiety after stroke.  
Conclusion 
There is low quality evidence to suggest psychotherapy and pharmacotherapy may be 
effective interventions in the treatment of anxiety after stroke. However, the evidence is from 
underpowered studies that carried high risk of bias. Large-scale well-designed definitive trials 
are needed to establish whether pharmacotherapy or psychotherapy works. Our review 
highlighted key considerations for investigators wishing to design high quality trials to 
evaluate treatments for anxiety after stroke 
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Table 1.Characteristics of included studies . I indicates intervention; C, control; n, number; 
SD, standard deviation; IQR, interquartile range; NA, data not available; DASS, Depression 
Anxiety Stress Scales; DSM-IV, Diagnostic Statistical Manual of Mental Disorders, fourth 
edition; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; CCMD, Chinese 
Classification of Mental Disorders, third version; HAMA, Hamilton Anxiety Rating Scale; 
HAMD, Hamilton Rating Scale for Depression; SAS, Zung Self-Rating Anxiety Scale. STAI, 
State Trait Anxiety Inventory. 
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Figure 1. PRISMA diagram of included studies 
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(16/10/17) 
195 
Total titles identified 
n = 11126 
Records after duplicates removed 
n = 8218 
Titles and abstracts screened  
n = 8218 
Full text articles assessed for eligibility 
n =59 
Excluded 45 studies: 
15 not RCT 
11 did not 
target anxiety 
5 not ABI 
2 mild TBI 
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veterans only  
8 duplicated 
publication 
1 study* eligible but 
excluded as ongoing 
trial 
CINAHL 
(16/10/17) 
19 
Studies included 
n =14 
*Lamas K, Does touch massage facilitate recovery after stroke? 
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Figure 2. Effect sizes, meta-analysis, and bias assessment for included studies 
ABI, acquired brain injury; IV, inverse variance; CI, confidence intervals; UC, usual care; TBI, 
traumatic brain injury; CBT, cognitive behavioural therapy; CRT, cognitive remediation therapy;  
Risk of bias 
(A) Random sequence generation (selection bias) 
(B) Allocation concealment (selection bias) 
(C) Blinding of participants and personnel (performance bias) 
(D) Blinding of outcome assessment (detection bias) 
(E) Incomplete outcome data (attrition bias) 
(F) Selective reporting (reporting bias) 
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Highlights 
 A systematic review of trials of anxiety interventions for stroke and acquired brain 
injury 
 Some evidence to suggest efficacy of psycho- and pharmacotherapy interventions  
 Key aspects of trial design and sources of bias are summarized and discussed  
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